Literature DB >> 29998025

Oxaliplatin-induced bronchiolitis obliterans organizing pneumonia following hyperthermic intraperitoneal chemotherapy.

Guillaume Le Baut1, Jean-Marc Guilloit2, Vincent Leprince2, Yann Ollivier3, Catherine Dubos-Arvis2, Pascal Do2, Jasmine Sutter4, Ludovic Loge5, Radj Gervais2.   

Abstract

Oxaliplatin given systemically is associated with pneumonitis in less than 1% of cases. This case report describes acute respiratory failure, due to bronchiolitis organising pneumonia, in a patient with colorectal carcinoma being treated with hyperthermic intraperitoneal chemotherapy which included oxaliplatin and CPT-11 (irinotecan). The clinical course, the lack of an identifiable infectious agent and the complete response to corticosteroids suggested a drug-induced cause. After ruling out CPT-11, oxaliplatin was considered to be the causal agent. The unusual feature of this case was that pneumonitis developed after intraperitoneal administration of oxaliplatin. Oxaliplatin-associated respiratory complications can occur whatever route the drug is administered.

Entities:  

Keywords:  Bronchiolitis obliterans organizing pneumonia (BOOP); colorectal cancer; hyperthermic intraperitoneal chemotherapy; oxaliplatin

Year:  2018        PMID: 29998025      PMCID: PMC6006037          DOI: 10.21037/jgo.2018.01.01

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  14 in total

1.  Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy.

Authors:  R Trisolini; L Lazzari Agli; D Tassinari; D Rondelli; A Cancellieri; M Patelli; F Falcone; V Poletti
Journal:  Eur Respir J       Date:  2001-07       Impact factor: 16.671

Review 2.  Cellular and molecular pharmacology of oxaliplatin.

Authors:  Eric Raymond; Sandrine Faivre; Stephen Chaney; Jan Woynarowski; Esteban Cvitkovic
Journal:  Mol Cancer Ther       Date:  2002-01       Impact factor: 6.261

3.  Clarification of clinical features of interstitial lung disease induced by irinotecan based on postmarketing surveillance data and spontaneous reports.

Authors:  Noritoshi Yoshii; Tadamichi Suzuki; Masaki Nagashima; Akira Kon; Koji Kakihata; Akihiko Gemma
Journal:  Anticancer Drugs       Date:  2011-07       Impact factor: 2.248

4.  Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis.

Authors:  D Elias; C Honoré; F Dumont; M Ducreux; V Boige; D Malka; P Burtin; C Dromain; D Goéré
Journal:  Ann Surg       Date:  2011-08       Impact factor: 12.969

Review 5.  Oxaliplatin-related side effects: characteristics and management.

Authors:  Jim Cassidy; Jean-Louis Misset
Journal:  Semin Oncol       Date:  2002-10       Impact factor: 4.929

6.  Is acute dyspnea related to oxaliplatin administration?

Authors:  L M Pasetto; S Monfardini
Journal:  World J Gastroenterol       Date:  2006-09-28       Impact factor: 5.742

7.  Cryptogenic organizing pneumonitis during oxaliplatin chemotherapy for colorectal cancer: case report.

Authors:  Marcelo Garrido; Andrés O'Brien; Sergio González; José Miguel Clavero; Eric Orellana
Journal:  Chest       Date:  2007-12       Impact factor: 9.410

8.  Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.

Authors:  L Rubbia-Brandt; V Audard; P Sartoretti; A D Roth; C Brezault; M Le Charpentier; B Dousset; P Morel; O Soubrane; S Chaussade; G Mentha; B Terris
Journal:  Ann Oncol       Date:  2004-03       Impact factor: 32.976

9.  Fatal pneumonitis induced by oxaliplatin.

Authors:  Sara Arévalo Lobera; Naiara Sagastibeltza Mariñelarena; Ibone Elejoste Echeberría; Mireia Melé Olivé; Larraitz Egaña Otaño; Laura Basterretxea Badiola; Adelaida La Casta Muñoa; Mikel Azkue Gabilondo
Journal:  Clin Transl Oncol       Date:  2008-11       Impact factor: 3.405

10.  Oxaliplatin-Induced Pulmonary Toxicity in Gastrointestinal Malignancies: Two Case Reports and Review of the Literature.

Authors:  Mor Moskovitz; Mira Wollner; Nissim Haim
Journal:  Case Rep Oncol Med       Date:  2015-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.